Australian Trial to Test Medicinal Cannabis Against Chemotherapy’s Gut Side Effects

The CANCAN protocol describes a rigorous phase II randomised controlled trial asking whether prophylactic CBD/THC sublingual wafers can prevent gastrointestinal mucositis and its downstream symptom cascade in adults with advanced cancer receiving mucotoxic chemotherapy, though no results have yet been reported.

Why This Matters

Chemotherapy-induced gastrointestinal mucositis is a common and debilitating consequence of cytotoxic cancer therapy, triggering a cascade of secondary symptoms including diarrhoea, malnutrition, pain, and fatigue that collectively degrade quality of life and drive hospitalisation. There are currently no approved interventions to prevent this symptom cluster, leaving clinicians to manage each consequence reactively and in isolation. The endocannabinoid system’s established role in gut inflammation, pain modulation, and appetite regulation provides a scientifically grounded rationale for investigating cannabinoid-based prophylaxis. The publication of this protocol now signals that a carefully designed trial is underway, making it a critical moment for clinicians to understand what is being tested and what remains unknown.

Clinical Summary

Gastrointestinal mucositis caused by mucotoxic chemotherapy remains one of the most burdensome and poorly prevented complications in oncology, cascading into diarrhoea, malnutrition, anorexia, pain, fatigue, and sleep disturbance. Published in BMJ Open in 2025, the CANCAN (CANnabinoids in CANcer) protocol describes a phase II, double-blind, placebo-controlled randomised trial designed to test whether daily prophylactic administration of CBD (300 mg/day) plus participant-titrated THC (5 to 20 mg/day) delivered via sublingual wafers can reduce gastrointestinal mucositis burden across three cycles of chemotherapy. The mechanistic rationale rests on well-documented endocannabinoid system involvement in gut epithelial integrity, inflammation, nociception, and appetite regulation, with CBD contributing anti-inflammatory properties and THC providing antiemetic and analgesic effects.

Because this is a protocol paper, no efficacy or safety data are available. The trial targets 176 adults with solid or haematological cancers at four South Australian hospitals, using a tiered enrichment strategy to focus analysis on patients who actually develop mucositis. The primary outcome is patient-reported gastrointestinal mucositis burden measured by the validated Mucositis Daily Questionnaire. Secondary outcomes include overall symptom burden, anorexia, depression and anxiety, financial toxicity, quality of life, and healthcare utilisation. Key limitations acknowledged by the investigators include the risk of high dropout driven by the burden of daily electronic questionnaires, driving restrictions associated with THC, and the extended study duration. The authors are explicit that results are needed before any clinical recommendations can be considered.

Dr. Caplan’s Take

This is exactly the kind of trial design I want to see when patients ask whether cannabis can help with the gut side effects of their chemotherapy. The mechanistic logic connecting endocannabinoid signaling to mucosal inflammation, appetite, and pain is legitimate, and the CANCAN investigators have built a protocol that takes the question seriously with proper blinding, placebo control, and validated patient-reported outcomes. But I have to be clear with patients and colleagues alike: a well-designed protocol is not evidence of benefit. We have no results yet. The gap between plausible mechanism and proven clinical effect is precisely what this trial exists to narrow.

In practice, when a patient undergoing mucotoxic chemotherapy asks about cannabis for gut symptoms, I explain that a rigorous trial is underway but that we cannot yet recommend prophylactic cannabinoids for mucositis prevention based on current evidence. I focus on what is supported: optimizing existing supportive care, managing symptoms as they arise with validated approaches, and ensuring that any interest in medicinal cannabis is discussed openly with the oncology team rather than pursued independently. If results from CANCAN are positive, that conversation will change substantially, but we are not there yet.

Clinical Perspective

This protocol sits at an early but essential point in the research arc for cannabinoid-based supportive care in oncology. While a prior phase II trial has demonstrated benefit of combined CBD/THC for chemotherapy-induced nausea and vomiting, no comparable evidence exists for the prevention of gastrointestinal mucositis or its broader symptom cluster. The CANCAN design addresses this gap with appropriate methodological rigor, including a tiered enrichment strategy that ensures the analysis population reflects patients who actually experience the target condition. Until results are reported, however, the evidence does not support recommending cannabinoid prophylaxis for chemotherapy-induced gut toxicity in any patient population.

Clinicians should note several pharmacological considerations relevant to this trial and to patient inquiries. THC carries well-established psychoactive and sedation effects, and the protocol’s allowance for participant-titrated dosing (5 to 20 mg/day) reflects the wide variability in THC tolerability. Drug interactions between cannabinoids and chemotherapeutic agents, particularly those metabolized via CYP3A4 and CYP2C19, remain incompletely characterized. The most actionable recommendation now is to document patient interest in cannabinoid-based supportive care, discuss the absence of preventive evidence honestly, and flag the CANCAN trial as a study worth tracking for future clinical guidance.

Study at a Glance

Study Type

Published protocol for a phase II, randomised, double-blind, placebo-controlled trial

Trial Name

CANCAN (CANnabinoids in CANcer)

Population

Adults with solid or haematological cancers receiving mucotoxic chemotherapy

Intervention

CBD 300 mg/day plus THC 5 to 20 mg/day (participant-titrated) as sublingual wafers

Comparator

Matched placebo sublingual wafers

Primary Outcome

GI mucositis burden via Mucositis Daily Questionnaire

Sample Size

176 participants, randomised 1:1

Journal

BMJ Open

Year

2025

Registration

ACTRN12622000419763

Funding Source

Not specified in available protocol data

What Kind of Evidence Is This

This is a published trial protocol, not a completed study. Protocol papers occupy a foundational but pre-evidential position in the evidence hierarchy. They enable methodological transparency, allow peer scrutiny of design decisions before results could influence interpretation, and support trial pre-registration. However, the critical inference constraint is absolute: a protocol paper provides no data on whether the intervention is effective, safe, or superior to placebo. It can only be evaluated on the quality and rigor of its planned methodology.

How This Fits With the Broader Literature

The CANCAN protocol extends a small but growing body of research exploring medicinal cannabis in oncology supportive care. The most directly relevant precedent is a phase II RCT by Grimison and colleagues demonstrating that combined oral THC/CBD reduced chemotherapy-induced nausea and vomiting compared to placebo, providing proof of concept for cannabinoid combination therapy in this population. However, that trial addressed emesis, not gastrointestinal mucositis, and the leap from antiemetic effect to mucosal protection involves distinct biological pathways. Preclinical data on cannabinoid modulation of gut inflammation and epithelial barrier function support the hypothesis, but clinical translation remains unproven.

If CANCAN reports positive results, it would represent the first controlled clinical evidence for cannabinoid-based prevention of chemotherapy-induced GI mucositis, a space where no other pharmacological prophylaxis has been approved. Negative or equivocal results would also be informative, helping to calibrate the field’s expectations for cannabinoid utility beyond nausea and pain management.

Common Misreadings

The most likely overinterpretation of this publication is treating it as evidence that cannabis works for chemotherapy gut side effects. It does not. The CANCAN paper is a description of a trial that has been designed and is underway, not a report of outcomes. Citing this protocol as support for clinical use of cannabinoids in mucositis prevention would be a fundamental misreading of the evidence type. Similarly, the detailed mechanistic rationale presented in the protocol, while scientifically grounded, should not be conflated with demonstrated clinical benefit. Biological plausibility is a necessary condition for investigating an intervention, not a sufficient condition for recommending one.

Bottom Line

The CANCAN protocol establishes a methodologically sound framework for testing whether prophylactic CBD/THC can prevent chemotherapy-induced gastrointestinal mucositis, addressing a genuine and significant unmet clinical need. It provides no efficacy or safety data. Clinicians should recognize this as a trial worth monitoring closely but should not alter current supportive care recommendations on its basis. The field awaits results before any evidence-based conclusions about cannabinoid prophylaxis for GI mucositis can be drawn.

References

1. CANCAN Trial Protocol. CANnabinoids in CANcer: a phase II randomised, double-blind, placebo-controlled trial of CBD/THC sublingual wafers for the prevention of chemotherapy-induced gastrointestinal mucositis. BMJ Open. 2025. Trial registration: ACTRN12622000419763.
2. Grimison P, Mersiades A, Kirber A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553-1560.